<SEC-DOCUMENT>0001193125-25-270286.txt : 20251107
<SEC-HEADER>0001193125-25-270286.hdr.sgml : 20251107
<ACCEPTANCE-DATETIME>20251106184431
ACCESSION NUMBER:		0001193125-25-270286
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20251106
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251107
DATE AS OF CHANGE:		20251106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eledon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36620
		FILM NUMBER:		251459958

	BUSINESS ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eldn-20251106.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-11-06T16:35:59.9676+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:eldn="http://www.eledon.com/20251106" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_94aa9a7a-d147-45e8-86c8-bb136161de30" name="dei:AmendmentFlag" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee">false</ix:nonNumeric><ix:nonNumeric id="F_02c5eabe-ff3c-4fa9-9522-f160675e2fac" name="dei:EntityCentralIndexKey" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee">0001404281</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="eldn-20251106.xsd"/></ix:references><ix:resources><xbrli:context id="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-06</xbrli:startDate><xbrli:endDate>2025-11-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b7d291b-7d2d-49af-96cf-0385cddbfa66" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_665009f9-decb-4653-abc8-4e252807f0df" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">November 06, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83765916-d377-439a-8fae-b7166fc4d89d" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eledon Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5c46ab3d-c2f9-4a80-96d1-b14ec1ce6bfb" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e17af036-d3ba-4891-9180-54faadc620a7" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-36620</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1d31360f-ae62-4b0a-85b7-a3b60c91ad42" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">20-1000967</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e16c6199-d5bf-4762-bbd5-0a8ee6f2a316" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19800 MacArthur Blvd.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a2095c09-427b-4bb2-a23b-236e4cb31477" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 250</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_648c7967-d3c0-4bf3-9fd2-798259a64610" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Irvine</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_cca4b2af-0fda-4ec9-a7cd-c18ba7a0b000" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b1f66ce8-ed6d-4a38-84c9-0b9d3f511988" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92612</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_de6dcef2-6b3b-4bb8-968e-f4f5f3036bca" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">949</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_f53057a9-92da-44b6-a004-32cf68af0c64" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">238-8090</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9fcd73c9-8cd4-458d-8ce8-64ba2061d91a" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c225096a-7e65-4d32-92b1-f1b1078ae873" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d2a103d-9d44-41db-b03a-e14c72a1ea0b" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_324dffb7-be8a-4852-9af9-73388da289e2" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0b2775de-b2b6-4abd-9cb9-f0c1c416923d" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6e63be59-9fdb-43a8-9388-865b82c6a30c" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ELDN</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d35f2b75-920a-4630-b11b-cfbc300fad60" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_0ab0a4e4-e612-4719-9363-def8c45eef94" contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 6, 2025, Eledon Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing that its estimated cash, cash equivalents, and short-term investments as of September 30, 2025 was approximately $93.4 million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This amount is unaudited and preliminary and is subject to completion of financial closing procedures, including the completion of management&#8217;s review. As a result, this amount reflects the Company&#8217;s preliminary estimate with respect to its cash, cash equivalents and short-term investments position as of September 30, 2025, based on information currently available to management, and may vary from the Company&#8217;s actual financial position as of September 30, 2025 that will be reported in a Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 that the Company will file with the U.S. Securities and Exchange Commission. Further, this preliminary estimate is not a comprehensive statement or estimate of the Company&#8217;s financial data or financial condition as of September 30, 2025. The unaudited preliminary financial data included in this Item 2.02 has been prepared by, and is the responsibility of, the Company&#8217;s management. The Company&#8217;s independent registered public accounting firm has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the unaudited preliminary financial data and, accordingly, does not express an opinion or any other form of assurance with respect thereto.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in Item 2.02 of this Current Report on Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 6, 2025, the Company issued a press release announcing results from its Phase 2 BESTOW trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a de novo kidney transplant. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 7, 2025 and as previously disclosed, the Company is hosting a conference call to discuss the updated Phase 2 BESTOW clinical data. Information about how to access the conference call is included in the press release attached hereto as Exhibit 99.1. A copy of the presentation for the conference call will be posted on the Company&#8217;s website at https://ir.eledon.com/investor-relations prior to the conference call.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act, nor shall it be, or be deemed, incorporated by reference in any filings under the Securities Act or Exchange Act, except as expressly set forth by specific reference in such a filing.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:13%;box-sizing:content-box;"/>
     <td style="width:87%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:13%;box-sizing:content-box;"/>
     <td style="width:87%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eldn-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release, dated November 6, 2025, announcing Phase 2 BESTOW trial results.</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Eledon Pharmaceuticals, Inc.</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 6, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ David-Alexandre C. Gros, M.D.</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: David Alexandre C. Gros, M.D.<br/>Title: Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>eldn-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-11-06T16:35:59.9813+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><img src="img20068692_0.jpg" alt="img20068692_0.jpg" style="width:186px;height:47px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology&#x2019;s Kidney Week 2025 Annual Meeting</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m&sup2;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Tegoprubart demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Conference call to be held Friday, November 7 at 8:00 a.m. ET</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">IRVINE, Calif., November 06, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> (&#x201c;Eledon&#x201d;) (NASDAQ: ELDN) today announced results from its Phase 2 BESTOW trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a de novo kidney transplant. Results from the Phase 2 BESTOW clinical trial were presented today as a late breaking oral presentation titled &#x201c;Efficacy and Safety of Tegoprubart for the Prevention of Rejection in Kidney Transplantation: Results from the Phase 2 BESTOW Trial,&#x201d; at the American Society of Nephrology&#x2019;s Kidney Week 2025 Annual Meeting in Houston, TX.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;The Phase 2 BESTOW data results demonstrate tegoprubart&#x2019;s potential to maintain excellent kidney function while reducing the chronic metabolic, neurologic, and cardiovascular toxicities that burden patients on tacrolimus,&#x201d; said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. &#x201c;By pairing strong immunosuppressive efficacy with a differentiated safety profile, including dramatically lower rates of new-onset diabetes, tremor, and dialysis-requiring delayed graft function, tegoprubart represents a promising next-generation option for kidney transplant immunosuppression as we advance into Phase 3.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There remains a significant unmet need for safer alternatives to traditional tacrolimus-based immunosuppression regimens&#x2014;options that can reduce harmful side effects without compromising efficacy. The Phase 2 results presented at ASN Kidney Week highlight the potential of tegoprubart to deliver strong graft function after kidney transplantation, while avoiding the long-term toxicities often associated with current standard of care,&#x201d; said Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief, Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota. &#x201c;It&#x2019;s been more than a decade since we&#x2019;ve seen true innovation in transplant immunosuppression. These data offer real</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">hope that patients may soon have a transformative therapy that improves their health outcomes and overall quality of life.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Study Design</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The 12-month, randomized, head-to-head, Phase 2 study enrolled 127 kidney transplant recipients (63 receiving tegoprubart and 64 receiving tacrolimus) across 44 global sites. The study directly compared tegoprubart-based immunosuppression with a tacrolimus-based regimen. All patients also received rabbit antithymocyte globulin (rATG) induction and maintenance therapy with mycophenolate mofetil (MMF/MPA) and corticosteroids.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The study&#x2019;s primary efficacy endpoint was the change in eGFR at 12 months post-transplant. Secondary endpoints included biopsy-proven acute rejection (BPAR), patient and graft survival, composite efficacy failure, iBox score, donor-specific antibodies (DSAs), delayed graft function (DGF), and new-onset diabetes after transplantation (NODAT).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Safety Results</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Safety findings underscore tegoprubart&#x2019;s potential to maintain effective immunosuppression while minimizing the metabolic, neurologic, and cardiovascular toxicities characteristic of tacrolimus-based therapy.</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Metabolic effects:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> New-onset diabetes developed in approximately 1 in 6 patients receiving tacrolimus versus 1 in 47 receiving tegoprubart.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Neurologic effects:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Tremor was markedly higher in the tacrolimus group (25.0% vs. 1.6%).</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cardiovascular effects:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Hypertension (15.9% vs. 25.0%), hypertensive crisis (1.6% vs. 7.8%), and heart failure (0% vs. 4.7%) all favored tegoprubart.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Renal recovery:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Delayed graft function occurred less often with tegoprubart and required shorter dialysis (14.3% vs. 25.0%; 4.6 days vs. 6.1 days), suggesting potential reductions of 115 days on dialysis post-transplant per 100 deceased donor kidney recipients on tegoprubart vs. tacrolimus.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Infections: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Sepsis or bacteremia occurred more frequently in the tacrolimus arm (17.2% vs. 4.8%). Viral infection rates (CMV, BK, EBV, fungal) were similar across groups, with no cases of Post-Transplant Lymphoproliferative Disorder (PTLD) or Progressive Multifocal Leukoencephalopathy (PML).</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Overall rates of serious adverse events were comparable between treatment arms.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Efficacy Results</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">eGFR on tegoprubart treatment was 69 mL/min/1.73 m&sup2; (n=51) at 12 months vs. 66 mL/min/1.73 m&sup2; for tacrolimus (n=56). Although the primary endpoint did not reach statistical significance, tegoprubart maintained strong renal function, delivering what the Company believes is the highest mean eGFR level reported to date in kidney transplant clinical trials evaluating rejection prevention.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Subgroup analyses demonstrated higher eGFRs in nearly all tegoprubart subgroups compared with tacrolimus, particularly among living-related donor recipients (~72 mL/min/1.73 m&sup2; vs. 62 mL/min/1.73 m&sup2;) and high Kidney Donor Profile Index (KDPI &gt; 35) transplants (~62 mL/min/1.73 m&sup2; vs. 53 mL/min/1.73 m&sup2;).</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In the deceased donor subgroup, tegoprubart achieved a mean eGFR of approximately 68 mL/min/1.73 m&sup2; at 12 months.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The efficacy failure composite endpoint, comprising death, graft loss and biopsy proven acute rejection, is the approval endpoint currently recognized by the U.S. Food and Drug Administration. Efficacy failure composite endpoint was 22% in the tegoprubart group vs. 17% in the tacrolimus group, demonstrating non-inferiority for tegoprubart vs. tacrolimus, using a 20% non-inferiority margin. The Company believes these results, if replicated in a Phase 3 study, would be sufficient to support tegoprubart&#x2019;s approvability.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The rate of acute rejection in all biopsies was 20.6% in the tegoprubart group compared with 14.1% in the tacrolimus group.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Among patients in the tegoprubart group who experienced acute rejection and remained on treatment through month 12, mean eGFR was 73 mL/min/1.73 m&sup2;, compared with 50 mL/min/1.73 m&sup2; in those who switched to tacrolimus.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There was 1 case of donor-specific antibodies (DSA) in the tegoprubart arm vs. 2 in the tacrolimus arm.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Next Steps</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Based on these results, Eledon plans to advance tegoprubart into Phase 3 development following discussions with regulators on study design and data requirements. Insights from the Phase 2 BESTOW data set and the ongoing long-term extension study will be incorporated to optimize the Phase 3 protocol and strengthen the regulatory package.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Estimated cash, cash equivalents and short-term investments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> totaled approximately $93.4 million as of September 30, 2025. The company expects current cash, cash equivalents and short-term investments to fund operations to late 2026.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Conference Call</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Eledon will hold a conference call on November 7, 2025, at 8:00 a.m. Eastern Time to discuss the Phase 2 BESTOW trial results presented at Kidney Week. The dial-in numbers are 1-800-717-1738 for domestic callers and 1-646-307-1865 for international callers. The conference ID is 92427. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">www.eledon.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The webcast will be archived on the website following the completion of the call and a copy of the presentation for the conference call will be posted on the Company&#x2019;s website at https://ir.eledon.com/investor-relations prior to the conference call.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Full details of the oral presentation are below:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Title: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Efficacy and Safety of Tegoprubart for the Prevention of Rejection in Kidney Transplantation: Results from the Phase 2 BESTOW Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Session Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  Late-Breaking Research Orals - 1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Presenter: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> <br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Session Date and Time: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">November 6, 2025, from 4:30 p.m. to 6:00 p.m. CT</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Eledon is also conducting an ongoing open label Phase 1b study (</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">NCT05027906</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">) and a long-term safety and efficacy extension study (</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">NCT06126380</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">) to evaluate tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Participants who complete 12 months of treatment in the Phase 1b and Phase 2 BESTOW trials are eligible to enroll into the long-term extension study.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">About Eledon Pharmaceuticals and tegoprubart</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company&#x2019;s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company&#x2019;s website at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">www.eledon.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Follow Eledon Pharmaceuticals on social media: </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">; </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Twitter</font></font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Statement Regarding Preliminary Financial Information</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The cash, cash equivalents and short-term investments presented in this press release is unaudited and preliminary and is subject to completion of financial closing procedures, including the completion of management&#x2019;s review. The preliminary financial information is based on information currently available to management, and may vary from the amounts that will be reported in Eledon&#x2019;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 that the Company will file with the U.S. Securities and Exchange Commission.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company&#x2019;s future expectations, plans and prospects, including statements about ongoing, planned and future clinical trials, the development of product candidates, expected or future results of tegoprubart trials and its ability to prevent rejection in connection with kidney transplantation, submissions to regulators, our expected cash, cash equivalents and short-term investments as well as other statements containing the words &#x201c;believes,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;plans,&#x201d; &#x201c;expects,&#x201d; &#x201c;estimates,&#x201d; &#x201c;intends,&#x201d; &#x201c;predicts,&#x201d; &#x201c;projects,&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;targets,&#x201d; &#x201c;looks forward,&#x201d; &#x201c;could,&#x201d; &#x201c;may,&#x201d; and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sites, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company&#x2019;s capital resources to fund planned clinical trials; and uncertainties relating to the completion of our quarter-end closing procedures for our financial statements for the quarter ended September 30, 2025. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company&#x2019;s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">www.sec.gov</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Investor Contact:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stephen Jasper<br>Gilmartin Group<br>(858) 525 2047<br></font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">stephen@gilmartinir.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Media Contact:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Jenna Urban<br>CG Life<br>(212) 253 8881</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">jurban@cglife.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Source: Eledon Pharmaceuticals</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img20068692_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img20068692_0.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !1 3X# 2(  A$! Q$!_\0
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MO#=I?Z?/KFK:WXBTC3[1]2TNQ2XGU/5=-L;O] J_B/\ ^#Q[_G'/_P!W=_\
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MOB#P[K/A6ZUC77M?$?BJ_P!<6STC7;U]+T^WGT:&#4Q!>7DFH0Q"S(!]L_\
M!<3]LKXW?L)_L#>+?CQ^SYJ/A_1_B5#\0/ '@W3]7\2>'[7Q/9Z78>*]0N[7
M4+ZTTC4'_LV;4X(X$:R?4K:_L8W+&XL+E2%'YX_\&['_  6!_:'_ ."@][\;
M_@9^U7J7AWQ?\3/A9X9\-_$+PA\1M$\,Z+X/U/Q5X4U#59?#GBBQ\5:#X7M-
M)\*I?:%J]SX:GTN_\/Z%I$=U;ZY?6]]:![&UGN/9/^#HK_E%)XN_[+=\&?\
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M_P#R>S^TM_V:S<?^K:^&]?OA_P '17_**3Q=_P!EN^#/_IYU&OP/_P"#0_\
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MC1]*TO6?''Q2:PN(9;>YUJRBU_1?#/@:_9_^)%>0^,M16U.JIX>U/2P#\./
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MQZ7-K%QI<.H6YA@U[3='U0V\=W86[1?Z'G_!?3_E$-^VK_V)/@;_ -7%\.:
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M(QDYUF4445^9']%A7\1__!X]_P XY_\ N[O_ -]@K^W"OXC_ /@\>_YQS_\
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M28^*'ANW\06_[6WACP-<O% U_P"&/B?X9\;>!_$FD7$ZNWV*YAU/PZ=)U.6
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M-UJOB >+M<L+GQL\C:UI\<\%Q;1R2VT8/N_[/G_!6K_@GUXH_9-^'GQIU_\
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M)7BK2X_#/A'X@^*M'BG\,Z<]IK,D5K=>*?#\UN >R?&WX:?\%6OV6O@QXO\
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M^7?_ (.N?^1H_9C_ .O#3/\ U.KROZB/^"?_ /R9;^S9_P!DL\/_ /H$M%%
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>_7Q9_**OU9_X(X_\H\O@+_UX^(O_ %)-3HHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>eldn-20251106.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-11-06T16:36:00.3402+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.eledon.com/20251106" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:eldn="http://www.eledon.com/20251106" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eldn-20251106.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  06,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eledon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001404281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-1000967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">19800 MacArthur Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-8090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELDN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="eldn-20251106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="eldn-20251106.htm">eldn-20251106.htm</File>
    <File>eldn-20251106.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "eldn-20251106.htm": {
   "nsprefix": "eldn",
   "nsuri": "http://www.eledon.com/20251106",
   "dts": {
    "inline": {
     "local": [
      "eldn-20251106.htm"
     ]
    },
    "schema": {
     "local": [
      "eldn-20251106.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20251106.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20251106.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.eledon.com/20251106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001193125-25-270286-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-270286-xbrl.zip
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MOR-8"_J.(AF&<D0^!A&+>,!"TJEZ/0 P>8T<AR&YPFHIN9*I3&ZEJ!6-=C/
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MW=UOAIV5V*$CZ_Y_(WX;\?NLW'U9&HRUE;]KRK@17 :FNQ$!2!FF"@2%N]$
MUB1KJE6>LJW^7J?[G-V"'];K#)ZW-K*TD:6'EZ7C1;"UKO+T_1P8&SX0H-SJ
M[74.K:20S(!O%I:_ P3U 1]*\.I0C.BJ_<[!<^? A8)*5*Q_R+:<P.UV]I^W
M& ;VJ$9T,=RQ$<2-(#Z\(+X7F/X&5(4AYOG:">!)<VA$^91<#E@$SIY+/]NZ
MYJ58I*TVP:J64&D,F!1U*""FNYV=FC2/0!H'+.!S0]\-.CWZT,*B[.D4"_P!
M<U9>*"7[;0$ ^(.]WIZ]%>96/F$I(,5 -%FOV\4TL""GD2)#1:2U%EY=VI>
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M\JL7VV$61R__'U!+ 0(4 Q0    ( (Z59EMT] \RV!8  %O#   1
M      "  0    !E;&1N+3(P,C4Q,3 V+FAT;5!+ 0(4 Q0    ( (Z59EN,
MZPB9@ @  !-A   1              "  0<7  !E;&1N+3(P,C4Q,3 V+GAS
M9%!+ 0(4 Q0    ( (Z59ELI-+[SSQD  !VH   /              "  ;8?
G  !E;&1N+65X.3E?,2YH=&U02P4&      ,  P"[    LCD

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>eldn-20251106_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eldn-20251106.xsd" xlink:type="simple"/>
    <context id="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <startDate>2025-11-06</startDate>
            <endDate>2025-11-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_94aa9a7a-d147-45e8-86c8-bb136161de30">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_02c5eabe-ff3c-4fa9-9522-f160675e2fac">0001404281</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_4b7d291b-7d2d-49af-96cf-0385cddbfa66">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_665009f9-decb-4653-abc8-4e252807f0df">2025-11-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_83765916-d377-439a-8fae-b7166fc4d89d">Eledon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_5c46ab3d-c2f9-4a80-96d1-b14ec1ce6bfb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_e17af036-d3ba-4891-9180-54faadc620a7">001-36620</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_1d31360f-ae62-4b0a-85b7-a3b60c91ad42">20-1000967</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_e16c6199-d5bf-4762-bbd5-0a8ee6f2a316">19800 MacArthur Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_a2095c09-427b-4bb2-a23b-236e4cb31477">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_648c7967-d3c0-4bf3-9fd2-798259a64610">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_cca4b2af-0fda-4ec9-a7cd-c18ba7a0b000">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_b1f66ce8-ed6d-4a38-84c9-0b9d3f511988">92612</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_de6dcef2-6b3b-4bb8-968e-f4f5f3036bca">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_f53057a9-92da-44b6-a004-32cf68af0c64">238-8090</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_9fcd73c9-8cd4-458d-8ce8-64ba2061d91a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_c225096a-7e65-4d32-92b1-f1b1078ae873">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_9d2a103d-9d44-41db-b03a-e14c72a1ea0b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_324dffb7-be8a-4852-9af9-73388da289e2">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_0b2775de-b2b6-4abd-9cb9-f0c1c416923d">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_6e63be59-9fdb-43a8-9388-865b82c6a30c">ELDN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_d35f2b75-920a-4630-b11b-cfbc300fad60">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_1a684c8f-78a2-449e-85da-3c3fcd6cd2ee"
      id="F_0ab0a4e4-e612-4719-9363-def8c45eef94">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
